Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW study in retinopathy of prematurity
2014-003041-10Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab in retinopathy of prematurity (ROP) (2 arms), sponsored by Novartis. Primary endpoint: Absence of active ROP and absence of unfavorable structural outcomes in both eyes at 24 weeks. Started Jan 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2014-003041-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003041-10.